A Phase I Study of Gemcitabine + Dasatinib (GD) or Gemcitabine + Dasatinib + Cetuximab (GDC) in Refractory Solid Tumors

PURPOSE: This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabine + dasatinib (GD) and gemcitabine + dasatinib + cetuximab (GDC) in advanced solid tumor patients. METHODS: This study was a standard phase I 3+3 dose escalati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Main Authors: Mettu, Niharika B, Niedzwiecki, Donna, Rushing, Christel, Nixon, Andrew B., Jia, Jingquan, Haley, Sherri, Honeycutt, Wanda, Hurwitz, Herbert, Bendell, Johanna C., Uronis, Hope
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8040291/
https://ncbi.nlm.nih.gov/pubmed/30895346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03805-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares